We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood and Body Fluid Analyzer Developed for Medium-Sized Labs

By LabMedica International staff writers
Posted on 21 May 2009
A new, automatic analyzer has been developed for analysis of blood and body fluids in hospitals with medium-sized laboratories. More...
The analyzer will play an important part in the diagnosis of a number of diseases, including different types of infection and leukemia.

Automated digital cell morphology is the process by which cells are automatically located on a stained peripheral blood or body fluid smear, preclassified, stored, and presented for confirmation by a technologist. The images then become available for access by physicians at any time for perusal.

Using the new analyzer laboratories can achieve time reductions (up to 50 %) and more standardized analyses. To count and classify white blood cells is a very common routine analysis in hematology laboratories. Trends indicate that medium-sized laboratories would like to automate the analytical process. Increased automation gives lab personnel more time and increases objectivity, safety, and standardization in the analytical work.

Called CellaVision DM1200, the instrument is CellaVision's (Lund, Sweden) next generation analyzer, and is the latest addition to the company's current range of products that include CellaVision DM96 and CellaVision DM8. The new instrument is based on a new cost-reduced hardware platform, is automated, and has a wider range of uses. Body fluid software can be added to the analyzer for analysis of fluids such as cerebrospinal fluid.

The official product launch will take place at the international Annual Meeting & Clinical Lab Expo AACC in Chicago, USA, on July 20-24, 2009. CellaVision DM1200 will be commercially available in Europe in around the same time.

CellaVision AB develops and markets systems for automatic differentials of white blood cells and erythrocyte morphology, and software for education and quality assurance of differentials.

Related Links:

CellaVision



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.